Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

FDA approves new drug lecanemab for the treatment of Alzheimer’s disease

Staff Writer
Staff Writer 3 weeks ago
Updated 2023/01/07 at 8:56 AM
Share
SHARE

On January 6th, 2013, the US Food and Drug Administration approved a new drug capable of slowing cognitive decline among patients with early stages or mild Alzheimer’s disease.

The drug, known as Leqembi, or lecanemab, was approved through an accelerated process.

“Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones,” according to one FDA official.

The official described Leqembi as “the latest therapy to target and affect the underlying disease process of Alzheimer’s, instead of only treating the symptoms of the disease.”


In clinical trials, the drug was purported to slow cognitive decline among Alzheimer’s patients by up to 27 percent.

The trial data was published and available in the New England Journal of Medicine.

You Might Also Like

New study explores test that can detect Alzheimer’s years before diagnosis

New research explores the association between viral infection and Alzheimer’s disease

Prenatal exposure to pollution may be linked to lower cognitive scores in infants

Researchers unveil new drug candidate to help treat adrenoleukodystrophy

New research finds Alzheimer’s risk factors affect males and females very differently

TAGGED: lecanemab, Leqembi, Alzheimer's disease
Staff Writer January 6, 2023
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article New study finds women who experience IPV are at a significantly higher risk of HIV
Next Article Researchers explore effectiveness of combat-related PTSD treatment

Recommended

Clinical

New study explores test that can detect Alzheimer’s years before diagnosis

1 Min Read
Health

New research explores the association between viral infection and Alzheimer’s disease

1 Min Read
Clinical

Prenatal exposure to pollution may be linked to lower cognitive scores in infants

1 Min Read
Clinical

Researchers unveil new drug candidate to help treat adrenoleukodystrophy

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?